Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 2Gastrointestinal 1CNS 1Breast 1

Conditions

Breast Neoplasms 74Colorectal Neoplasms 43Rectal Neoplasms 41Stomach Neoplasms 39Triple Negative Breast Neoplasms 31Neoplasm Metastasis 20Esophageal Neoplasms 16Colonic Neoplasms 16Neoplasms 13Pancreatic Neoplasms 12Parkinson Disease 4, Autosomal Dominant Lewy Body 11Adenocarcinoma 11Nasopharyngeal Carcinoma 10Biliary Tract Neoplasms 10Adenocarcinoma Of Esophagus 9Cholangiocarcinoma 7Locally Advanced Rectal Cancer 6Esophageal Squamous Cell Carcinoma 6Anus Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Neuroendocrine Tumors 5Gastrointestinal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 5Ovarian Neoplasms 4HER2-positive Breast Cancer 4Colorectal Cancer Metastatic 4Carcinoma, Hepatocellular 4Advanced Solid Tumors 4

Interventions

Cyclophosphamide 49fludarabine 36Dexamethasone 35venetoclax 29pembrolizumab 26Rituximab 21Lenalidomide 18pomalidomide 17Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 11carfilzomib 11Temozolomide 11Cisplatin 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Injections 9Azacitidine 9selinexor 8Vincristine 8Carboplatin 8Bortezomib 8obinutuzumab 7Immunotherapy, Adoptive 7Bevacizumab 7zanubrutinib 6ruxolitinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recurrence × Capecitabine × 1 year × Clear all
NCT02669173 2026-02-23

Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma

Case Comprehensive Cancer Center

Phase 1 Completed
12 enrolled
CNS

Brain Neoplasms, Glioblastoma, Recurrence

NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3 Not yet recruiting
400 enrolled
Breast

Breast Neoplasms, Recurrence

NCT05126719 2026-02-06

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Shanghai Miracogen Inc.

Phase 2 Active not recruiting
238 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT06976190 2026-01-20

Magic-C002

Shanghai Miracogen Inc.

Phase 3 Recruiting
446 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT05990543 2025-09-08

Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer

Korea University Anam Hospital

Phase 1/2 Active not recruiting
59 enrolled
Gastrointestinal

Recurrence, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡